Second Tranche Of $91 Million Venture Round Will Help Advance Two Formulations Of Radius’ Osteoporosis Drug

Radius, which reverse-merged into a public company this past May, has advanced an injectable formulation of BA058 into Phase III, while it is preparing to move a transdermal version into Phase II.